progesterone receptor


Also found in: Acronyms, Wikipedia.

progesterone receptor

[MIM*607311]
intracellular receptor for progesterone; often overexpressed in breast cancer.

progesterone receptor

A progesterone-binding protein complex found in the cytoplasm of certain cells in particular of the breast, which belongs to the nuclear receptor family. See Progesterone receptor assay. Cf Estrogen receptor.

pro·ges·ter·one re·cep·tor

(prō-jes'tĕr-ōn rĕ-sep'tŏr)
Intracellular receptor for progesterone; often overexpressed in breast cancer.
References in periodicals archive ?
MEST often display immunoreactivity for estrogen and progesterone receptors, but this is not necessary for diagnosis, as morphology is sufficient.
Progesterone receptor immunoreactivity existed in the nucleus of mature oocytes (moderately positive; Fig.
American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer.
Aggressive angiomyxoma of pelvic parts exhibits estrogen and progesterone receptor positivity.
In 6 cases, the tumor was both progesterone receptor negative and exhibited a mitotic count score of 3, and in all these cases the Recurrence Score was high.
The study "places the progesterone receptor right in the middle of the physiology" of BRCA1-related breast cancers, says physician Steven Narod of the University of Toronto.
CDB-2914 is a member of a class of drugs known as progesterone receptor modulators, which also bind to the progesterone receptor, preventing progesterone from binding with it.
Progesterone receptor (PR) mRNA was upregulated in the Ishikawa endometrial cancer cell line.
However, the human progesterone receptor (hPR) has high homology (87%) with the hAR.
The findings were reported in a poster entitled "Characterization of progesterone receptor biomarker for predicting antiprogestin in human cancers," presented today at the 35th Annual San Antonio Breast Cancer Symposium.
Progesterone receptor (PR) and human epidermal growth factor receptor 2 (HER2/neu) were negative by immunohistochemistry (Figure 3) with a proliferative fraction of 20%.
It remains my paramount goal, both as an executive and physician, to advance the clinical development of onapristone, which is currently being evaluated in a Phase I trial in women with progesterone receptor expressing tumors and a Phase I/II trial in men with advanced, castration-resistant prostate cancer, as well as plan for the continued development of our two additional compounds, AR-42 and AR-12.